Investors Chronicle5 Sep 2014 11:27
Buy ahead of Clinigen re-rating
After listing in late 2012, pharmaceutical group Clinigen (CLIN) fast become the darling of London's junior Aim market. The listing price - 164p - surged to 690p early this year, but some disappointments in half-year results in February led to a substantial share price fall. But with strong full-year numbers looking likely when the company reports its figures later this month, we think there is now considerable ground to make up on the upside. Investors therefore have a second opportunity to buy the stock, this time at a significant discount to 2013 levels.
If there's anything else I can't get it!